Bitcoin's seven-day average hashrate fell to about 915.8 EH/s, the lowest in three weeks, indicating reduced mining power securing the network. Miner-held Bitcoin reserves also declined by 1,530 BTC to roughly 1.193 million BTC, reflecting ongoing sales or transfers from miner wallets. Despite these declines, the Puell Multiple rose to 1.13, suggesting daily miner revenue remains above the yearly average. Mining conditions vary globally, with some operators shifting resources to AI computing, impacting Bitcoin mining capacity and activity.
Bitcoin's mining activity shows signs of change, with Pluang's market snapshot providing context as of Sep 27, 2026 15:31 WIB: among 50 major cryptocurrencies tradable on Pluang, 35 rose and 14 fell today. Notable movers include KSM (Kusama) at Rp88.689 with a 1-day change of +4.91% and 100% sell order activity, UNI (Uniswap) at Rp180.381 with +4.81% and 60% buy order activity, and ATOM (Cosmos) at Rp34.102 with +3.97% and 66% buy order activity.
Bitcoin held steady around $84,626, marking a 0.84% daily gain and a 43.5% rise this quarter, its best Q3 since 2017. U.S. spot Bitcoin ETFs attracted $2.4 billion last week, the largest weekly inflow in nearly a year, signaling strong institutional ...
Solana (SOL) has risen above $120 for the first time since January, gaining about 8% in a week amid strong market momentum. This surge follows the deployment of the Alpenglow network upgrade on devnet, which aims to drastically reduce transaction fin...
Chainlink has seen large holders add over 2.5 million LINK tokens in the past 10 days, signaling strong confidence and potential for price gains. Nearly 1,500 new LINK addresses are created daily, indicating steady network growth and adoption. The to...
Large holders, or whales, have purchased over 1.14 billion Dogecoin tokens worth $112 million in the past 96 hours as the price struggles to break the key resistance around $0.10. This aggressive accumulation during price dips has been a recurring pa...
Annexon is focusing its clinical trials on maintaining functional outcomes for patients with geographic atrophy and Guillain-Barré syndrome, aiming to show real-world benefits like vision and physical recovery preservation. The ARCHER II trial now ta...
